Inquest: HCA's Lister Hospital Skipped VTE Prophylaxis in 80-Year-Old

For health system and patient-safety leaders, the Westminster inquest into the death of Lady Joan Branson is not a celebrity story—it is a stark clinical process failure. An 80-year-old woman with acute pelvic and hip fractures and prolonged immobility was assessed as 'extremely high risk' for venous thromboembolism but received no prophylactic anticoagulation from admission to death at HCA Healthcare's Lister Hospital. The coroner's nuanced conclusion that this was 'not neglect' but still a failure that contributed to a preventable pulmonary embolism should prompt every chief medical officer and clinical governance team to audit their own VTE risk-assessment and prophylaxis compliance.

The conclusion of an inquest at Westminster Coroner's Court has drawn unusually sharp attention to a gap in private-sector hospital safety: the omission of routine venous thromboembolism prophylaxis in a patient whose clinical profile made a fatal blood clot highly foreseeable. Lady Joan Branson, 80, died on 24 November at HCA Healthcare's Lister Hospital in Chelsea after a pulmonary embolism, a sudden blockage of a lung artery caused by deep vein thrombosis. She had been admitted seven days earlier, on 17 November, after a fall at Necker Island, the private Caribbean retreat owned by her husband, Sir Richard Branson. The fall was described as tripping over slippers, but the injuries were serious: sustained pelvic fractures and right hip fractures. Those injuries, combined with immobility, put her in a category that clinical guidelines recognise as high risk for venous thromboembolism.

“

Lady Joan Branson, 80, died on 24 November at HCA Healthcare's Lister Hospital in Chelsea after a pulmonary embolism, a sudden blockage of a lung artery caused by deep vein thrombosis.

Despite that, the inquest heard that Lady Joan received no prophylactic anticoagulation from admission until death. Haematologist Dr George Adams, an Imperial College London academic not involved in her care, told the court she was "extremely high risk" for blood clots and that "the biggest risk factor by far was her immobility and her fracture." He went further: "appropriate anticoagulation" would have "probably prevented her from dying." That is a stark assessment in a coronial setting, where causation must be weighed carefully. It also brings the failure squarely into the realm of preventable harm rather than an unavoidable clinical outcome.

The coroner, Professor Fiona Wilcox, balanced the clinical evidence against questions of culpability. She described Lady Joan as a "wonderful woman" and concluded it was "not a case of neglect" and "wasn't an absence of treatment." Yet she also stated that Lady Joan did not receive prophylactic anticoagulants. The distinction matters. It suggests a systems failure in risk assessment or protocol execution rather than deliberate disregard. From a governance perspective, that is both reassuring and troubling: reassuring because no individual was found to have deliberately withheld care, but troubling because the absence of prophylaxis across an entire seven-day admission indicates a breakdown in routine clinical processes.

For HCA Healthcare, one of the world's largest private hospital operators, the case has implications beyond one patient. The Lister Hospital in Chelsea is a high-profile private facility in central London. Coroners' conclusions, while not criminal findings, can lead to Prevention of Future Deaths reports and influence Care Quality Commission inspections and clinical governance reviews. A high-profile case involving the Branson family is likely to prompt immediate internal audits of venous thromboembolism risk assessment, prescribing, and missed-dose monitoring across HCA's UK sites. The inquest record did not detail the hospital's internal risk-assessment documentation, but the fact that zero prophylactic anticoagulation was administered over a week is itself a red flag for protocol adherence.